CA2235368A1 - Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor - Google Patents

Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor Download PDF

Info

Publication number: CA2235368A1
Authority: CA; Canada
Prior art keywords: cugauga; gaa; nucleic acid; vegf; rna
Prior art date: 1995-10-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002235368A

Other languages

English (en)

French (fr)

Inventor

Pamela Pavco

James Mcswiggen

Dan T. Stinchcomb

Jaime Escobedo

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis Vaccines and Diagnostics Inc

Sirna Therapeutics Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-10-26

Filing date

1996-10-25

Publication date

1997-05-01

1996-10-25 Application filed by Individual filed Critical Individual

1997-05-01 Publication of CA2235368A1 publication Critical patent/CA2235368A1/en

Status Abandoned legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims description 27
238000011282 treatment Methods 0.000 title claims description 27
201000010099 disease Diseases 0.000 title description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 14
108091008605 VEGF receptors Proteins 0.000 title description 13
102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 title description 13
239000003153 chemical reaction reagent Substances 0.000 title description 8
229940124676 vascular endothelial growth factor receptor Drugs 0.000 title description 2
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 127
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract description 126
150000007523 nucleic acids Chemical class 0.000 claims abstract description 80
102000039446 nucleic acids Human genes 0.000 claims abstract description 78
108020004707 nucleic acids Proteins 0.000 claims abstract description 78
108020004999 messenger RNA Proteins 0.000 claims abstract description 40
230000014509 gene expression Effects 0.000 claims abstract description 28
230000015572 biosynthetic process Effects 0.000 claims abstract description 12
238000003786 synthesis reaction Methods 0.000 claims abstract description 9
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims abstract description 4
108091092562 ribozyme Proteins 0.000 claims description 270
108090000994 Catalytic RNA Proteins 0.000 claims description 267
102000053642 Catalytic RNA Human genes 0.000 claims description 267
108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 134
210000004027 cell Anatomy 0.000 claims description 101
101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 claims description 69
101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 claims description 66
239000002773 nucleotide Substances 0.000 claims description 39
125000003729 nucleotide group Chemical group 0.000 claims description 39
230000000694 effects Effects 0.000 claims description 34
108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 31
102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 claims description 28
230000002255 enzymatic effect Effects 0.000 claims description 28
102000005962 receptors Human genes 0.000 claims description 28
108020003175 receptors Proteins 0.000 claims description 28
241000282414 Homo sapiens Species 0.000 claims description 23
239000000758 substrate Substances 0.000 claims description 22
230000000692 anti-sense effect Effects 0.000 claims description 16
230000000295 complement effect Effects 0.000 claims description 11
210000004962 mammalian cell Anatomy 0.000 claims description 8
239000013604 expression vector Substances 0.000 claims description 7
241000724709 Hepatitis delta virus Species 0.000 claims description 6
210000005260 human cell Anatomy 0.000 claims description 5
108091027874 Group I catalytic intron Proteins 0.000 claims description 2
108020005544 Antisense RNA Proteins 0.000 claims 1
239000003184 complementary RNA Substances 0.000 claims 1
241000251131 Sphyrna Species 0.000 description 84
238000003776 cleavage reaction Methods 0.000 description 36
230000007017 scission Effects 0.000 description 33
239000000243 solution Substances 0.000 description 31
230000005764 inhibitory process Effects 0.000 description 26
230000033115 angiogenesis Effects 0.000 description 24
239000013598 vector Substances 0.000 description 21
239000003795 chemical substances by application Substances 0.000 description 19
108090000623 proteins and genes Proteins 0.000 description 19
210000004087 cornea Anatomy 0.000 description 18
230000001404 mediated effect Effects 0.000 description 17
238000012986 modification Methods 0.000 description 17
230000004048 modification Effects 0.000 description 17
238000006467 substitution reaction Methods 0.000 description 17
230000004663 cell proliferation Effects 0.000 description 15
238000000338 in vitro Methods 0.000 description 15
210000001519 tissue Anatomy 0.000 description 15
108020004414 DNA Proteins 0.000 description 14
108090001102 Hammerhead ribozyme Proteins 0.000 description 13
239000000203 mixture Substances 0.000 description 13
108050007372 Fibroblast Growth Factor Proteins 0.000 description 12
102000018233 Fibroblast Growth Factor Human genes 0.000 description 12
210000002889 endothelial cell Anatomy 0.000 description 12
229940126864 fibroblast growth factor Drugs 0.000 description 12
108010082117 matrigel Proteins 0.000 description 12
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical group [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 12
206010028980 Neoplasm Diseases 0.000 description 11
108091034117 Oligonucleotide Proteins 0.000 description 11
125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 11
102000040650 (ribonucleotides)n+m Human genes 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
238000002474 experimental method Methods 0.000 description 10
206010039073 rheumatoid arthritis Diseases 0.000 description 10
206010029113 Neovascularisation Diseases 0.000 description 9
238000003556 assay Methods 0.000 description 9
230000005747 tumor angiogenesis Effects 0.000 description 9
KKZFLSZAWCYPOC-VPENINKCSA-N Deoxyribose 5-phosphate Chemical compound O[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 KKZFLSZAWCYPOC-VPENINKCSA-N 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 8
238000010171 animal model Methods 0.000 description 8
239000000074 antisense oligonucleotide Substances 0.000 description 8
238000012230 antisense oligonucleotides Methods 0.000 description 8
210000004925 microvascular endothelial cell Anatomy 0.000 description 8
235000018102 proteins Nutrition 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
241000700159 Rattus Species 0.000 description 7
230000006870 function Effects 0.000 description 7
239000003102 growth factor Substances 0.000 description 7
238000001727 in vivo Methods 0.000 description 7
229940046166 oligodeoxynucleotide Drugs 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
241000702421 Dependoparvovirus Species 0.000 description 6
108010010803 Gelatin Proteins 0.000 description 6
229910019142 PO4 Inorganic materials 0.000 description 6
230000003197 catalytic effect Effects 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
239000008273 gelatin Substances 0.000 description 6
229920000159 gelatin Polymers 0.000 description 6
235000019322 gelatine Nutrition 0.000 description 6
235000011852 gelatine desserts Nutrition 0.000 description 6
230000035407 negative regulation of cell proliferation Effects 0.000 description 6
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
239000010452 phosphate Substances 0.000 description 6
239000000047 product Substances 0.000 description 6
210000001525 retina Anatomy 0.000 description 6
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical group OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
241000701161 unidentified adenovirus Species 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
241000699660 Mus musculus Species 0.000 description 5
201000011510 cancer Diseases 0.000 description 5
230000008878 coupling Effects 0.000 description 5
238000010168 coupling process Methods 0.000 description 5
238000005859 coupling reaction Methods 0.000 description 5
238000011161 development Methods 0.000 description 5
230000018109 developmental process Effects 0.000 description 5
239000000499 gel Substances 0.000 description 5
239000001963 growth medium Substances 0.000 description 5
230000006698 induction Effects 0.000 description 5
230000000670 limiting effect Effects 0.000 description 5
150000002632 lipids Chemical class 0.000 description 5
230000001177 retroviral effect Effects 0.000 description 5
239000000523 sample Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
238000013518 transcription Methods 0.000 description 5
230000035897 transcription Effects 0.000 description 5
239000013603 viral vector Substances 0.000 description 5
208000035657 Abasia Diseases 0.000 description 4
206010021143 Hypoxia Diseases 0.000 description 4
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
241000221960 Neurospora Species 0.000 description 4
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 4
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 4
201000004681 Psoriasis Diseases 0.000 description 4
230000007022 RNA scission Effects 0.000 description 4
239000004809 Teflon Substances 0.000 description 4
229920006362 Teflon® Polymers 0.000 description 4
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
230000001772 anti-angiogenic effect Effects 0.000 description 4
208000005017 glioblastoma Diseases 0.000 description 4
230000012010 growth Effects 0.000 description 4
108090001052 hairpin ribozyme Proteins 0.000 description 4
230000007954 hypoxia Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
238000002156 mixing Methods 0.000 description 4
238000011580 nude mouse model Methods 0.000 description 4
239000008188 pellet Substances 0.000 description 4
229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 4
230000035755 proliferation Effects 0.000 description 4
230000009467 reduction Effects 0.000 description 4
238000012552 review Methods 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
238000001356 surgical procedure Methods 0.000 description 4
HWCKGOZZJDHMNC-UHFFFAOYSA-M tetraethylammonium bromide Chemical compound [Br-].CC[N+](CC)(CC)CC HWCKGOZZJDHMNC-UHFFFAOYSA-M 0.000 description 4
230000004614 tumor growth Effects 0.000 description 4
OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
108091027075 5S-rRNA precursor Proteins 0.000 description 3
108020000948 Antisense Oligonucleotides Proteins 0.000 description 3
201000004569 Blindness Diseases 0.000 description 3
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 3
101710177611 DNA polymerase II large subunit Proteins 0.000 description 3
101710184669 DNA polymerase II small subunit Proteins 0.000 description 3
206010012689 Diabetic retinopathy Diseases 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
239000012124 Opti-MEM Substances 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
230000006819 RNA synthesis Effects 0.000 description 3
208000017442 Retinal disease Diseases 0.000 description 3
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 3
241000700605 Viruses Species 0.000 description 3
239000002253 acid Substances 0.000 description 3
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 3
239000004037 angiogenesis inhibitor Substances 0.000 description 3
238000005349 anion exchange Methods 0.000 description 3
238000013459 approach Methods 0.000 description 3
230000008901 benefit Effects 0.000 description 3
210000004204 blood vessel Anatomy 0.000 description 3
238000001516 cell proliferation assay Methods 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
230000000875 corresponding effect Effects 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000010586 diagram Methods 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 3
239000007943 implant Substances 0.000 description 3
238000011534 incubation Methods 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
230000003993 interaction Effects 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
239000002502 liposome Substances 0.000 description 3
210000004924 lung microvascular endothelial cell Anatomy 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
150000008300 phosphoramidites Chemical class 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
238000012216 screening Methods 0.000 description 3
239000007787 solid Substances 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
230000001052 transient effect Effects 0.000 description 3
241001430294 unidentified retrovirus Species 0.000 description 3
230000002792 vascular Effects 0.000 description 3
230000007998 vessel formation Effects 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
108020004635 Complementary DNA Proteins 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
RTDFOQVLLJZRIH-JZAVHCKJSA-N Glycoursocholanic acid Chemical compound C([C@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)CC1 RTDFOQVLLJZRIH-JZAVHCKJSA-N 0.000 description 2
102100033969 Guanylyl cyclase-activating protein 1 Human genes 0.000 description 2
208000037262 Hepatitis delta Diseases 0.000 description 2
101001068480 Homo sapiens Guanylyl cyclase-activating protein 1 Proteins 0.000 description 2
101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
229930182816 L-glutamine Natural products 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
208000022873 Ocular disease Diseases 0.000 description 2
108700020796 Oncogene Proteins 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
206010038923 Retinopathy Diseases 0.000 description 2
108091028664 Ribonucleotide Proteins 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 2
229960005054 acepromazine Drugs 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
239000002870 angiogenesis inducing agent Substances 0.000 description 2
230000002491 angiogenic effect Effects 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
210000002403 aortic endothelial cell Anatomy 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
230000003190 augmentative effect Effects 0.000 description 2
210000002469 basement membrane Anatomy 0.000 description 2
238000010804 cDNA synthesis Methods 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000011278 co-treatment Methods 0.000 description 2
238000001816 cooling Methods 0.000 description 2
230000002950 deficient Effects 0.000 description 2
238000011033 desalting Methods 0.000 description 2
-1 dimethoxytrityl Chemical group 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
238000007429 general method Methods 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
208000029570 hepatitis D virus infection Diseases 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
230000003054 hormonal effect Effects 0.000 description 2
102000055590 human KDR Human genes 0.000 description 2
238000003364 immunohistochemistry Methods 0.000 description 2
238000002513 implantation Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
239000012678 infectious agent Substances 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000002609 medium Substances 0.000 description 2
239000003226 mitogen Substances 0.000 description 2
230000035772 mutation Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
239000006187 pill Substances 0.000 description 2
244000000003 plant pathogen Species 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000002243 precursor Substances 0.000 description 2
230000001023 pro-angiogenic effect Effects 0.000 description 2
230000001185 psoriatic effect Effects 0.000 description 2
108091008598 receptor tyrosine kinases Proteins 0.000 description 2
102000027426 receptor tyrosine kinases Human genes 0.000 description 2
230000007115 recruitment Effects 0.000 description 2
239000002336 ribonucleotide Substances 0.000 description 2
125000002652 ribonucleotide group Chemical group 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
210000005222 synovial tissue Anatomy 0.000 description 2
239000003826 tablet Substances 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
230000007306 turnover Effects 0.000 description 2
210000003556 vascular endothelial cell Anatomy 0.000 description 2
230000008728 vascular permeability Effects 0.000 description 2
DLMXFZFNHPGUPW-ANYOKISRSA-N (2s)-2-[n-acetyl-4-[1-(4-hydroxy-2-oxochromen-3-yl)-3-oxobutyl]anilino]-5-amino-5-oxopentanoic acid Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=C(N([C@@H](CCC(N)=O)C(O)=O)C(C)=O)C=C1 DLMXFZFNHPGUPW-ANYOKISRSA-N 0.000 description 1
CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
102100027962 2-5A-dependent ribonuclease Human genes 0.000 description 1
108010000834 2-5A-dependent ribonuclease Proteins 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 1
XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
TYJOQICPGZGYDT-UHFFFAOYSA-N 4-methylsulfonylbenzenesulfonyl chloride Chemical compound CS(=O)(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 TYJOQICPGZGYDT-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
101150034533 ATIC gene Proteins 0.000 description 1
241000710929 Alphavirus Species 0.000 description 1
241001463143 Auca Species 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
101000909256 Caldicellulosiruptor bescii (strain ATCC BAA-1888 / DSM 6725 / Z-1320) DNA polymerase I Proteins 0.000 description 1
241000723343 Cichorium Species 0.000 description 1
235000007542 Cichorium intybus Nutrition 0.000 description 1
241000725101 Clea Species 0.000 description 1
241000518994 Conta Species 0.000 description 1
208000028006 Corneal injury Diseases 0.000 description 1
241000192700 Cyanobacteria Species 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
101000686777 Escherichia phage T7 T7 RNA polymerase Proteins 0.000 description 1
241000701533 Escherichia virus T4 Species 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
102000001690 Factor VIII Human genes 0.000 description 1
108010054218 Factor VIII Proteins 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
201000010915 Glioblastoma multiforme Diseases 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
108091080980 Hepatitis delta virus ribozyme Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
241001174911 Iasis Species 0.000 description 1
102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
108010083687 Ion Pumps Proteins 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
240000007817 Olea europaea Species 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
229920000153 Povidone-iodine Polymers 0.000 description 1
241000288906 Primates Species 0.000 description 1
102100029812 Protein S100-A12 Human genes 0.000 description 1
101710110949 Protein S100-A12 Proteins 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
101000902592 Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) DNA polymerase Proteins 0.000 description 1
108010013845 RNA Polymerase I Proteins 0.000 description 1
102000017143 RNA Polymerase I Human genes 0.000 description 1
108010078067 RNA Polymerase III Proteins 0.000 description 1
102000014450 RNA Polymerase III Human genes 0.000 description 1
108091008103 RNA aptamers Proteins 0.000 description 1
208000007135 Retinal Neovascularization Diseases 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
102000004389 Ribonucleoproteins Human genes 0.000 description 1
108010081734 Ribonucleoproteins Proteins 0.000 description 1
101100256149 Salmonella typhimurium (strain 14028s / SGSC 2262) sarA gene Proteins 0.000 description 1
108020005543 Satellite RNA Proteins 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
241000282887 Suidae Species 0.000 description 1
101710137500 T7 RNA polymerase Proteins 0.000 description 1
241000223892 Tetrahymena Species 0.000 description 1
241001092905 Thermophis Species 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 1
108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
238000007792 addition Methods 0.000 description 1
UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical group C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
125000005103 alkyl silyl group Chemical group 0.000 description 1
230000006427 angiogenic response Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000003527 anti-angiogenesis Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000037429 base substitution Effects 0.000 description 1
239000000227 bioadhesive Substances 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
230000003399 chemotactic effect Effects 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
210000003763 chloroplast Anatomy 0.000 description 1
238000007398 colorimetric assay Methods 0.000 description 1
108091036078 conserved sequence Proteins 0.000 description 1
239000013068 control sample Substances 0.000 description 1
239000013256 coordination polymer Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
238000011461 current therapy Methods 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000002716 delivery method Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
238000006642 detritylation reaction Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
229960000301 factor viii Drugs 0.000 description 1
210000004996 female reproductive system Anatomy 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
210000003128 head Anatomy 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000008863 intramolecular interaction Effects 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
230000002262 irrigation Effects 0.000 description 1
238000003973 irrigation Methods 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
229960004184 ketamine hydrochloride Drugs 0.000 description 1
229960004194 lidocaine Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
210000004088 microvessel Anatomy 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
239000000178 monomer Substances 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
239000002088 nanocapsule Substances 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000003322 phosphorimaging Methods 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
230000035409 positive regulation of cell proliferation Effects 0.000 description 1
230000030114 positive regulation of endothelial cell proliferation Effects 0.000 description 1
238000010149 post-hoc-test Methods 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
229960001621 povidone-iodine Drugs 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000135 prohibitive effect Effects 0.000 description 1
201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
230000004224 protection Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
238000011555 rabbit model Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000033458 reproduction Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
208000032253 retinal ischemia Diseases 0.000 description 1
201000009410 rhabdomyosarcoma Diseases 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
210000001423 scleral cell Anatomy 0.000 description 1
238000003375 selectivity assay Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
241000894007 species Species 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
210000001179 synovial fluid Anatomy 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
101150065190 term gene Proteins 0.000 description 1
238000013334 tissue model Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
231100000588 tumorigenic Toxicity 0.000 description 1
230000000381 tumorigenic effect Effects 0.000 description 1
210000003954 umbilical cord Anatomy 0.000 description 1
229960005356 urokinase Drugs 0.000 description 1
230000006444 vascular growth Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1
230000029663 wound healing Effects 0.000 description 1
230000037314 wound repair Effects 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960004175 xylazine hydrochloride Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/122—Hairpin
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

CA002235368A 1995-10-26 1996-10-25 Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor Abandoned CA2235368A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US597495P	1995-10-26	1995-10-26
US60/005,974		1995-10-26
US08/584,040 US6346398B1 (en)	1995-10-26	1996-01-11	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US08/584,040		1996-01-11
PCT/US1996/017480 WO1997015662A2 (en)	1995-10-26	1996-10-25	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

Publications (1)

Publication Number	Publication Date
CA2235368A1 true CA2235368A1 (en)	1997-05-01

Family

ID=26674998

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002235368A Abandoned CA2235368A1 (en)	1995-10-26	1996-10-25	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

Country Status (7)

Country	Link
US (5)	US6346398B1 (2)
EP (1)	EP0859837A2 (2)
JP (1)	JP2000504925A (2)
AU (1)	AU7666296A (2)
CA (1)	CA2235368A1 (2)
DE (1)	DE69638198D1 (2)
WO (1)	WO1997015662A2 (2)

Families Citing this family (208)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0642589A4 (en) *	1992-05-11	1997-05-21	Ribozyme Pharm Inc	METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
US20030206887A1 (en) *	1992-05-14	2003-11-06	David Morrissey	RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
US6710174B2 (en) *	2001-09-13	2004-03-23	Isis Pharmaceuticals, Inc.	Antisense inhibition of vascular endothelial growth factor receptor-1 expression
US5639647A (en) *	1994-03-29	1997-06-17	Ribozyme Pharmaceuticals, Inc.	2'-deoxy-2'alkylnucleotide containing nucleic acid
WO2002096927A2 (en) *	2001-05-29	2002-12-05	Ribozyme Pharmaceuticals, Incorporated	Ribozyme based treatment of female reproductive diseases
US6346398B1 (en) *	1995-10-26	2002-02-12	Ribozyme Pharmaceuticals, Inc.	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US20040220128A1 (en) *	1995-10-26	2004-11-04	Sirna Therapeutics, Inc.	Nucleic acid based modulation of female reproductive diseases and conditions
US20040142895A1 (en) *	1995-10-26	2004-07-22	Sirna Therapeutics, Inc.	Nucleic acid-based modulation of gene expression in the vascular endothelial growth factor pathway
US7097829B2 (en) *	1996-11-21	2006-08-29	Cedars-Sinai Medical Center	Transgenic cells transfected with pituitary tumor transforming gene (PTTG)) expression vectors and uses therefor
US6894031B1 (en) *	1996-11-21	2005-05-17	Cedars-Sinai Medical Center	Pituitary tumor transforming gene (PTTG) carboxy-terminal peptides and methods of use thereof to inhibit neoplastic cellular proliferation and/or transformation
US6455305B1 (en) *	1996-11-21	2002-09-24	Cedars-Sinai Medical Center	Pituitary-tumor-transforming-genes, and related products
US20050096282A1 (en) *	1997-04-21	2005-05-05	Lewin Alfred S.	Adeno-associated virus-delivered ribozyme compositions and methods for the treatment of retinal diseases
EP1321521A1 (en) *	1997-05-09	2003-06-25	Ribozyme Pharmaceuticals, Inc.	Ribozymes directed against flt-1
WO1999004819A1 (en) *	1997-07-24	1999-02-04	Inex Pharmaceuticals Corporation	Liposomal compositions for the delivery of nucleic acid catalysts
US20030104973A1 (en) *	1997-08-21	2003-06-05	Quark Biotech, Inc.	Hypoxia-regulated genes
US7973156B2 (en) *	1997-08-21	2011-07-05	Quark Pharmaceuticals Inc.	Hypoxia-regulated genes
US6518017B1 (en) *	1997-10-02	2003-02-11	Oasis Biosciences Incorporated	Combinatorial antisense library
AU757789B2 (en) *	1998-03-27	2003-03-06	Ribozyme Pharmaceuticals, Inc.	Method and reagents for the treatment of diseases or conditions related to molecules involved in angiogenic responses
EP1071753A2 (en) *	1998-04-20	2001-01-31	Ribozyme Pharmaceuticals, Inc.	Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
US6417169B1 (en) *	1998-04-23	2002-07-09	Genesense Technologies Inc.	Insulin-like growth factor II antisense oligonucleotide sequences and methods of using same to inhibit cell growth
US7087580B2 (en)	1998-04-23	2006-08-08	Genesense Technologies, Inc.	Neuropilin antisense oligonucleotide sequences and methods of using same to modulate cell growth
CA2328893A1 (en) *	1998-05-20	1999-11-25	Kyowa Hakko Kogyo Co., Ltd.	Vegf activity inhibitors
JP2002529421A (ja) *	1998-11-06	2002-09-10	ビーエーエスエフアクチェンゲゼルシャフト	血管過浸透性の阻害方法
AUPP795198A0 (en)	1998-12-24	1999-01-28	Commonwealth Scientific And Industrial Research Organisation	Miniribozymes active at low magnesium ion concentrations
DE19956568A1 (de)	1999-01-30	2000-08-17	Roland Kreutzer	Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
AU7368100A (en) *	1999-09-10	2001-04-10	Curagen Corporation	Fibroblast growth factor polypeptide and nucleic acids encoding same
WO2001023616A2 (en) *	1999-09-29	2001-04-05	Genetic Vectors, Inc.	Method of identifying pathogenic cryptococci
US7829693B2 (en) *	1999-11-24	2010-11-09	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of a target gene
US20080039414A1 (en) *	2002-02-20	2008-02-14	Sima Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US8202979B2 (en) *	2002-02-20	2012-06-19	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US8273866B2 (en) *	2002-02-20	2012-09-25	Merck Sharp & Dohme Corp.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
US20050032733A1 (en) *	2001-05-18	2005-02-10	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
AU2001295531A1 (en) *	2000-09-02	2002-03-13	Grünenthal GmbH	Antisense oligonucleotides against vanilloid receptor 1
US7125660B2 (en) *	2000-09-13	2006-10-24	Archemix Corp.	Nucleic acid sensor molecules and methods of using same
EP1325121A2 (en) *	2000-10-13	2003-07-09	Institut de Cardiologie de Montreal	Antisense oligonucleotide directed toward mammalian vegf receptor genes and uses thereof
AU9598601A (en) *	2000-10-20	2002-04-29	Eisai Co Ltd	Nitrogenous aromatic ring compounds
US8546143B2 (en)	2001-01-09	2013-10-01	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of a target gene
DE10106370B4 (de) *	2001-02-12	2005-01-27	Vermicon Ag	Oligonukleotidsonden zur Detektion von parodontopathogenen Bakterien mittels in situ-Hybridisierung
US20030171310A1 (en) *	2001-02-23	2003-09-11	Isis Pharmaceuticals Inc.	Antisense modulation of RECQL expression
EP1386004A4 (en) *	2001-04-05	2005-02-16	Ribozyme Pharm Inc	MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID
CA2441353A1 (en) *	2001-04-24	2002-10-31	Pharmacia & Upjohn Company	Single nucleotide polymorphisms diagnostic for schizophrenia
US20050153914A1 (en) *	2001-05-18	2005-07-14	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of MDR P-glycoprotein gene expression using short interfering nucleic acid (siNA)
US20050014172A1 (en) *	2002-02-20	2005-01-20	Ivan Richards	RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
US20050222066A1 (en) *	2001-05-18	2005-10-06	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050159379A1 (en) *	2001-05-18	2005-07-21	Sirna Therapeutics, Inc	RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA)
US20050124569A1 (en) *	2001-05-18	2005-06-09	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
US20050048529A1 (en) *	2002-02-20	2005-03-03	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
US20040198682A1 (en) *	2001-11-30	2004-10-07	Mcswiggen James	RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
US20050182007A1 (en) *	2001-05-18	2005-08-18	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20050164966A1 (en) *	2001-05-18	2005-07-28	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of type 1 insulin-like growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050164224A1 (en) *	2001-05-18	2005-07-28	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
US20050136436A1 (en) *	2001-05-18	2005-06-23	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of G72 and D-amino acid oxidase (DAAO) gene expression using short interfering nucleic acid (siNA)
WO2002097114A2 (en) *	2001-05-29	2002-12-05	Sirna Therapeutics, Inc.	Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
US20050267058A1 (en) *	2001-05-18	2005-12-01	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sINA)
US20090299045A1 (en) *	2001-05-18	2009-12-03	Sirna Therapeutics, Inc.	RNA Interference Mediated Inhibition Of Interleukin and Interleukin Gene Expression Using Short Interfering Nucleic Acid (siNA)
US20050079610A1 (en) *	2001-05-18	2005-04-14	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
WO2003070910A2 (en) *	2002-02-20	2003-08-28	Ribozyme Pharmaceuticals, Incorporated	INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20070042983A1 (en) *	2001-05-18	2007-02-22	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US9994853B2 (en)	2001-05-18	2018-06-12	Sirna Therapeutics, Inc.	Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20050176664A1 (en) *	2001-05-18	2005-08-11	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA)
US20050277133A1 (en) *	2001-05-18	2005-12-15	Sirna Therapeutics, Inc.	RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US20050159380A1 (en) *	2001-05-18	2005-07-21	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA)
US20070093437A1 (en) *	2001-05-18	2007-04-26	Sirna Therapeutics, Inc.	Rna interference mediated inhibition of xiap gene expression using short interfering nucleic acid (sina)
US20050187174A1 (en) *	2001-05-18	2005-08-25	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
US20050191618A1 (en) *	2001-05-18	2005-09-01	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
US20050148530A1 (en) *	2002-02-20	2005-07-07	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050119212A1 (en) *	2001-05-18	2005-06-02	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)
US20060142225A1 (en) *	2001-05-18	2006-06-29	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of cyclin dependent kinase-2 (CDK2) gene expression using short interfering nucleic acid (siNA)
US20050124567A1 (en) *	2001-05-18	2005-06-09	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of TRPM7 gene expression using short interfering nucleic acid (siNA)
US20050233344A1 (en) *	2001-05-18	2005-10-20	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA)
US20050158735A1 (en) *	2001-05-18	2005-07-21	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of proliferating cell nuclear antigen (PCNA) gene expression using short interfering nucleic acid (siNA)
US20050164968A1 (en) *	2001-05-18	2005-07-28	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA)
US20050288242A1 (en) *	2001-05-18	2005-12-29	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
US20050196781A1 (en) *	2001-05-18	2005-09-08	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of STAT3 gene expression using short interfering nucleic acid (siNA)
US20050209180A1 (en) *	2001-05-18	2005-09-22	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
US20060241075A1 (en) *	2001-05-18	2006-10-26	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
US20040019001A1 (en) *	2002-02-20	2004-01-29	Mcswiggen James A.	RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
US20050159378A1 (en) *	2001-05-18	2005-07-21	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
US7109165B2 (en) *	2001-05-18	2006-09-19	Sirna Therapeutics, Inc.	Conjugates and compositions for cellular delivery
US20050164967A1 (en) *	2001-05-18	2005-07-28	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
US20050282188A1 (en) *	2001-05-18	2005-12-22	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050159382A1 (en) *	2001-05-18	2005-07-21	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
US20050233997A1 (en) *	2001-05-18	2005-10-20	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US20040209831A1 (en) *	2002-02-20	2004-10-21	Mcswiggen James	RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
US20050256068A1 (en) *	2001-05-18	2005-11-17	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
US20050261219A1 (en) *	2001-05-18	2005-11-24	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
US20050176025A1 (en) *	2001-05-18	2005-08-11	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
US20070270579A1 (en) *	2001-05-18	2007-11-22	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050196765A1 (en) *	2001-05-18	2005-09-08	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
US20050176663A1 (en) *	2001-05-18	2005-08-11	Sima Therapeutics, Inc.	RNA interference mediated inhibition of protein tyrosine phosphatase type IVA (PRL3) gene expression using short interfering nucleic acid (siNA)
US20080188430A1 (en) *	2001-05-18	2008-08-07	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
US20050137155A1 (en) *	2001-05-18	2005-06-23	Sirna Therapeutics, Inc.	RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA)
US20050196767A1 (en) *	2001-05-18	2005-09-08	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
US20080161256A1 (en) *	2001-05-18	2008-07-03	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US7517864B2 (en) *	2001-05-18	2009-04-14	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050176666A1 (en) *	2001-05-18	2005-08-11	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of GPRA and AAA1 gene expression using short interfering nucleic acid (siNA)
US20050203040A1 (en) *	2001-05-18	2005-09-15	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
US20050143333A1 (en) *	2001-05-18	2005-06-30	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20060211642A1 (en) *	2001-05-18	2006-09-21	Sirna Therapeutics, Inc.	RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
US20050124566A1 (en) *	2001-05-18	2005-06-09	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
US20050287128A1 (en) *	2001-05-18	2005-12-29	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
EP1767632A3 (en) *	2001-05-29	2009-12-30	Sirna Therpeutics, Inc.	A method for local administration of synthetic double-stranded oligonucleotides targeting a VEGF receptor
JP2005515967A (ja) *	2001-07-13	2005-06-02	イムクローン　システムズ　インコーポレイティド	乳癌を治療するためのｖｅｇｆｒ−１抗体
US7968523B2 (en) *	2001-07-23	2011-06-28	Senesco Technologies, Inc.	Method for inducing apoptosis using apoptosis-specific EIF5-A
US6734017B2 (en) *	2001-09-28	2004-05-11	Isis Pharmaceuticals, Inc.	Antisense modulation of vascular endothelial growth factor receptor-2 expression
US6909030B2 (en) *	2001-10-15	2005-06-21	Cedars-Sinai Medical Center	PTTG knockout rodent as a model to study mechanisms for various physiological phenomena, including diabetes
US20070203333A1 (en) *	2001-11-30	2007-08-30	Mcswiggen James	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20040138163A1 (en) *	2002-05-29	2004-07-15	Mcswiggen James	RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050096284A1 (en) *	2002-02-20	2005-05-05	Sirna Therapeutics, Inc.	RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
AU2003219817B2 (en) *	2002-02-20	2006-08-31	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of hepatitis C virus
US9181551B2 (en)	2002-02-20	2015-11-10	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2006203062B2 (en) *	2002-02-20	2009-03-12	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US9657294B2 (en)	2002-02-20	2017-05-23	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7667030B2 (en) *	2002-02-20	2010-02-23	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
WO2003106476A1 (en) *	2002-02-20	2003-12-24	Sirna Therapeutics, Inc	Nucleic acid mediated inhibition of enterococcus infection and cytolysin toxin activity
EP1474433A4 (en) *	2002-02-20	2005-02-23	Sirna Therapeutics Inc	TARGET LOCALIZATION TARGETED BY RNA INTERFERENCE AND TARGET VALIDATION WITH SHORT INTERFERING NUCLEIC ACID (siNA)
US7700760B2 (en) *	2002-02-20	2010-04-20	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
EP1572713A4 (en) *	2002-08-14	2006-05-24	Pharmacia Corp	ANTISENSE MODULATION OF ACYL-COA SYNTHETASE 1 EXPRESSION
US7923547B2 (en)	2002-09-05	2011-04-12	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20040076621A1 (en) *	2002-10-16	2004-04-22	Isis Pharmaceuticals Inc.	Antisense modulation of CD36 expression
US20040077567A1 (en) *	2002-10-16	2004-04-22	Isis Pharmaceuticals Inc.	Antisense modulation of CD36 expression
US9771586B2 (en)	2002-11-14	2017-09-26	Thermo Fisher Scientific Inc.	RNAi targeting ZNF205
US20100113307A1 (en) *	2002-11-14	2010-05-06	Dharmacon, Inc.	siRNA targeting vascular endothelial growth factor (VEGF)
US7691998B2 (en) *	2002-11-14	2010-04-06	Dharmacon, Inc.	siRNA targeting nucleoporin 62kDa (Nup62)
US7951935B2 (en)	2002-11-14	2011-05-31	Dharmacon, Inc.	siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
US7781575B2 (en)	2002-11-14	2010-08-24	Dharmacon, Inc.	siRNA targeting tumor protein 53 (p53)
US7635770B2 (en) *	2002-11-14	2009-12-22	Dharmacon, Inc.	siRNA targeting protein kinase N-3 (PKN-3)
WO2006006948A2 (en)	2002-11-14	2006-01-19	Dharmacon, Inc.	METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US8198427B1 (en)	2002-11-14	2012-06-12	Dharmacon, Inc.	SiRNA targeting catenin, beta-1 (CTNNB1)
US9228186B2 (en)	2002-11-14	2016-01-05	Thermo Fisher Scientific Inc.	Methods and compositions for selecting siRNA of improved functionality
US10011836B2 (en)	2002-11-14	2018-07-03	Thermo Fisher Scientific Inc.	Methods and compositions for selecting siRNA of improved functionality
US20090227780A1 (en) *	2002-11-14	2009-09-10	Dharmacon, Inc.	siRNA targeting connexin 43
US9839649B2 (en)	2002-11-14	2017-12-12	Thermo Fisher Scientific Inc.	Methods and compositions for selecting siRNA of improved functionality
AU2003295600A1 (en)	2002-11-14	2004-06-15	Dharmacon, Inc.	Functional and hyperfunctional sirna
US7612196B2 (en) *	2002-11-14	2009-11-03	Dharmacon, Inc.	siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
US9719094B2 (en)	2002-11-14	2017-08-01	Thermo Fisher Scientific Inc.	RNAi targeting SEC61G
US9719092B2 (en)	2002-11-14	2017-08-01	Thermo Fisher Scientific Inc.	RNAi targeting CNTD2
US7592442B2 (en) *	2002-11-14	2009-09-22	Dharmacon, Inc.	siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
US9879266B2 (en)	2002-11-14	2018-01-30	Thermo Fisher Scientific Inc.	Methods and compositions for selecting siRNA of improved functionality
ATE508747T1 (de) *	2003-03-10	2011-05-15	Eisai R&D Man Co Ltd	C-kit kinase-hemmer
EP1606305A4 (en) *	2003-03-12	2009-06-24	Vasgene Therapeutics Inc	NUCLEIC ACID COMPOUNDS FOR THE INHIBITION OF ANGIOGENESIS AND TUMOR GROWTH
WO2004092383A2 (en) *	2003-04-15	2004-10-28	Sirna Therapeutics, Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS) VIRUS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2003241409A1 (en) *	2003-05-12	2005-01-21	Potomac Pharmaceuticals, Inc.	Gene expression suppression agents
CN100375750C (zh) *	2003-05-15	2008-03-19	中国疾病预防控制中心病毒病预防控制所	抑制人肿瘤坏死因子活性的寡聚核苷酸
US7683172B2 (en) *	2003-11-11	2010-03-23	Eisai R&D Management Co., Ltd.	Urea derivative and process for preparing the same
ATE452188T1 (de)	2004-02-10	2010-01-15	Sirna Therapeutics Inc	Rna-interferenz-vermittelte hemmung der genexpression unter verwendung multifunktioneller sina (short interfering nucleic acid)
US20060019914A1 (en) *	2004-02-11	2006-01-26	University Of Tennessee Research Foundation	Inhibition of tumor growth and invasion by anti-matrix metalloproteinase DNAzymes
JP2007531794A (ja)	2004-04-05	2007-11-08	アルニラムファーマスーティカルズインコーポレイテッド	オリゴヌクレオチドの合成および精製に使用する方法および反応試薬
EP1768998A2 (en)	2004-04-27	2007-04-04	Alnylam Pharmaceuticals Inc.	Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety
US8591885B2 (en)	2004-04-30	2013-11-26	Allergan, Inc.	Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US20060182783A1 (en) *	2004-04-30	2006-08-17	Allergan, Inc.	Sustained release intraocular drug delivery systems
AU2005323437B2 (en)	2004-04-30	2011-10-06	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising a C5-modified pyrimidine
US10508277B2 (en)	2004-05-24	2019-12-17	Sirna Therapeutics, Inc.	Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
EP1789553B1 (en)	2004-06-30	2014-03-26	Alnylam Pharmaceuticals Inc.	Oligonucleotides comprising a non-phosphate backbone linkage
WO2006093526A2 (en) *	2004-07-21	2006-09-08	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising a modified or non-natural nucleobase
AU2005330637B2 (en)	2004-08-04	2012-09-20	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase
ATE428421T1 (de)	2004-09-17	2009-05-15	Eisai R&D Man Co Ltd	Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
AU2005286663A1 (en) *	2004-09-23	2006-03-30	Vasgene Therapeutics, Inc.	Compositions and methods for detecting and treating tumors
JP5210634B2 (ja) *	2004-09-30	2013-06-12	イノジェネティックス・ナムローゼ・フェンノートシャップ	スペーサー領域を使用するセラチア（Ｓｅｒｒａｔｉａ）種の検出、同定および鑑別
JP4131271B2 (ja) *	2005-03-30	2008-08-13	ソニー株式会社	情報処理装置および方法、並びにプログラム
US7893244B2 (en) *	2005-04-12	2011-02-22	Intradigm Corporation	Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
CN101277704A (zh) *	2005-04-12	2008-10-01	因特拉迪格姆公司	用于治疗癌症及其它新血管生成疾病的RNAi治疗剂的组合物和方法
WO2007015569A1 (ja) *	2005-08-01	2007-02-08	Eisai R & D Management Co., Ltd.	血管新生阻害物質の効果を予測する方法
JP4989476B2 (ja)	2005-08-02	2012-08-01	エーザイ・アール・アンド・ディー・マネジメント株式会社	血管新生阻害物質の効果を検定する方法
US20090176725A1 (en) *	2005-08-17	2009-07-09	Sirna Therapeutics Inc.	Chemically modified short interfering nucleic acid molecules that mediate rna interference
CA2620594C (en) *	2005-09-01	2012-08-21	Eisai R&D Management Co., Ltd.	Pharmaceutical composition having improved disintegratability
US8168584B2 (en)	2005-10-08	2012-05-01	Potentia Pharmaceuticals, Inc.	Methods of treating age-related macular degeneration by compstatin and analogs thereof
AU2006309551B2 (en)	2005-11-07	2012-04-19	Eisai R & D Management Co., Ltd.	Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
EP1964837A4 (en) *	2005-11-22	2010-12-22	Eisai R&D Man Co Ltd	Antitumor agent against multiple myeloma
CN104706637A (zh) *	2006-05-18	2015-06-17	卫材R&D管理有限公司	针对甲状腺癌的抗肿瘤剂
JPWO2008001956A1 (ja) *	2006-06-29	2009-12-03	エーザイ・アール・アンド・ディー・マネジメント株式会社	肝線維症治療剤
WO2008026748A1 (en) *	2006-08-28	2008-03-06	Eisai R & D Management Co., Ltd.	Antitumor agent for undifferentiated gastric cancer
US8586556B2 (en)	2006-11-03	2013-11-19	Allergan, Inc.	Methods, compositions and drug delivery systems for intraocular delivery of siRNA molecules
US8039010B2 (en)	2006-11-03	2011-10-18	Allergan, Inc.	Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
CA2676796C (en) *	2007-01-29	2016-02-23	Eisai R & D Management Co., Ltd.	Composition for treatment of undifferentiated gastric cancer
EP2769731A1 (en)	2007-02-23	2014-08-27	The Trustees of Columbia University in the City of New York	Methods to activate or block the HLA-E/QA-1 restricted CD8+ T cell regulatory pathway to treat immunological disease
US11078262B2 (en)	2007-04-30	2021-08-03	Allergan, Inc.	High viscosity macromolecular compositions for treating ocular conditions
US8389215B2 (en) *	2007-07-26	2013-03-05	University Of Utah Research Foundation	Non-invasive recovery of RNA and analysis of gene expression in skin
CA2702039A1 (en) *	2007-10-12	2009-04-23	Intradigm Corporation	Therapeutic sirna molecules for reducing vegfr1 expression in vitro and in vivo
US8952035B2 (en)	2007-11-09	2015-02-10	Eisai R&D Management Co., Ltd.	Combination of anti-angiogenic substance and anti-tumor platinum complex
KR101506062B1 (ko) *	2008-01-29	2015-03-25	에자이 알앤드디 매니지먼트 가부시키가이샤	혈관 저해 물질과 탁산의 병용
US20090226531A1 (en) *	2008-03-07	2009-09-10	Allergan, Inc.	Methods and composition for intraocular delivery of therapeutic sirna
WO2010005527A1 (en)	2008-06-30	2010-01-14	Angioblast Systems, Inc.	Treatment of eye diseases and excessive neovascularization using a combined therapy
MY162940A (en)	2009-08-19	2017-07-31	Eisai R&D Man Co Ltd	Quinoline derivative-containing pharmaceutical composition
US9799416B2 (en) *	2009-11-06	2017-10-24	Terrapower, Llc	Methods and systems for migrating fuel assemblies in a nuclear fission reactor
US8618071B2 (en) *	2010-05-21	2013-12-31	Industrial Technology Research Institute	Oligonucleotides for suppressing cancer cell invasion and migration
CN102958523B (zh)	2010-06-25	2014-11-19	卫材R&D管理有限公司	使用具有激酶抑制作用的组合的抗肿瘤剂
WO2012058210A1 (en)	2010-10-29	2012-05-03	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
CN103402519B (zh)	2011-04-18	2015-11-25	卫材R&D管理有限公司	肿瘤治疗剂
JP6038128B2 (ja)	2011-06-03	2016-12-07	エーザイ・アール・アンド・ディー・マネジメント株式会社	レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
MX366404B (es)	2012-11-15	2019-07-08	Apellis Pharmaceuticals Inc	Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y composiciones y metodos relacionados.
KR20150098605A (ko)	2012-12-21	2015-08-28	에자이 알앤드디 매니지먼트 가부시키가이샤	퀴놀린 유도체의 비정질 형태 및 그의 제조방법
WO2014152391A1 (en)	2013-03-15	2014-09-25	Apellis Pharmaceuticals, Inc.	Cell-penetrating compstatin analogs and uses thereof
NZ714049A (en)	2013-05-14	2020-05-29	Eisai R&D Man Co Ltd	Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103627709A (zh) *	2013-12-06	2014-03-12	孙仑泉	抑制血管内皮生长因子受体基因表达的脱氧核酶
PT3524595T (pt)	2014-08-28	2022-09-19	Eisai R&D Man Co Ltd	Derivado de quinolina altamente puro e método para produção do mesmo
LT3263106T (lt)	2015-02-25	2024-01-10	Eisai R&D Management Co., Ltd.	Chinolino darinių kartumo sumažinimo būdas
KR102662228B1 (ko)	2015-03-04	2024-05-02	머크 샤프 앤드 돔 코포레이션	암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CN104831788A (zh) *	2015-05-08	2015-08-12	济南宏泰疏通技术有限公司	一种保护软轴疏通的装置
MX373231B (es)	2015-06-16	2020-05-08	Eisai R&D Man Co Ltd	Agente anticancerigeno.
US12220398B2 (en)	2015-08-20	2025-02-11	Eisai R&D Management Co., Ltd.	Tumor therapeutic agent
US11903994B2 (en)	2015-10-07	2024-02-20	Apellis Pharmaceuticals, Inc.	Dosing regimens
CA3043768A1 (en)	2016-11-29	2018-06-07	PureTech Health LLC	Exosomes for delivery of therapeutic agents
US12303505B2 (en)	2017-02-08	2025-05-20	Eisai R&D Management Co., Ltd.	Tumor-treating pharmaceutical composition
IL269844B2 (en)	2017-04-07	2025-01-01	Apellis Pharmaceuticals Inc	Dosage regimens and related compositions and methods
NO344051B1 (en) *	2017-05-04	2019-08-26	Patogen As	Novel virus in Fish and Method for detection
RU2019134940A (ru)	2017-05-16	2021-06-16	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Лечение гепатоцеллюлярной карциномы
WO2019118938A1 (en)	2017-12-15	2019-06-20	Apellis Pharmaceuticals, Inc.	Dosing regimens and related compositions and methods

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4987071A (en)	1986-12-03	1991-01-22	University Patents, Inc.	RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
CA1340323C (en)	1988-09-20	1999-01-19	Arnold E. Hampel	Rna catalyst for cleaving specific rna sequences
AU637800B2 (en)	1989-08-31	1993-06-10	City Of Hope	Chimeric dna-rna catalytic sequences
US5359051A (en)	1990-01-11	1994-10-25	Isis Pharmaceuticals	Compounds useful in the synthesis of nucleic acids capable of cleaning RNA
ES2061416T3 (es)	1990-10-12	1997-03-01	Max Planck Gesellschaft	Ribozimas modificadas.
DE4216134A1 (de)	1991-06-20	1992-12-24	Europ Lab Molekularbiolog	Synthetische katalytische oligonukleotidstrukturen
US5218285A (en)	1991-12-16	1993-06-08	Motorola, Inc.	Electronic device with dual purpose regulator
US5652094A (en)	1992-01-31	1997-07-29	University Of Montreal	Nucleozymes
US5496698A (en) *	1992-08-26	1996-03-05	Ribozyme Pharmaceuticals, Inc.	Method of isolating ribozyme targets
EP0642589A4 (en)	1992-05-11	1997-05-21	Ribozyme Pharm Inc	METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
US5525468A (en) *	1992-05-14	1996-06-11	Ribozyme Pharmaceuticals, Inc.	Assay for Ribozyme target site
AU687001B2 (en)	1992-05-14	1998-02-19	Ribozyme Pharmaceuticals, Inc.	Method and reagent for inhibiting cancer development
EP0786522A2 (en)	1992-07-17	1997-07-30	Ribozyme Pharmaceuticals, Inc.	Enzymatic RNA molecules for treatment of stenotic conditions
CN1701814A (zh)	1992-11-13	2005-11-30	马克斯普朗克科学促进协会	作为血管内皮生长因子受体的f1k－1
US6177401B1 (en) *	1992-11-13	2001-01-23	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften	Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
WO1994021791A1 (en) *	1993-03-16	1994-09-29	Johanna Eugenie Bergmann	Agents for the prevention and treatment of breast cancer
CA2158745C (en) *	1993-03-25	2007-06-19	Richard L. Kendall	Inhibitor of vascular endothelial cell growth factor
US6410322B1 (en)	1993-07-27	2002-06-25	Hybridon Inc	Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
WO1995004818A1 (en)	1993-08-06	1995-02-16	Ribozyme Pharmaceuticals, Inc.	Method and reagent for inhibiting human immunodeficiency virus replication
US5510239A (en) *	1993-10-18	1996-04-23	Isis Pharmaceuticals, Inc.	Oligonucleotide modulation of multidrug resistance-associated protein
US5861288A (en)	1993-10-18	1999-01-19	Ribozyme Pharmaceuticals, Inc.	Catalytic DNA
ATE226254T1 (de)	1993-11-12	2002-11-15	Ribozyme Pharm Inc	Reagenz zur behandlung von arthritischen zustaenden
US5840301A (en)	1994-02-10	1998-11-24	Imclone Systems Incorporated	Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
EP0746614A1 (en)	1994-02-23	1996-12-11	Ribozyme Pharmaceuticals, Inc.	Method and reagent for inhibiting the expression of disease related genes
US5631359A (en)	1994-10-11	1997-05-20	Ribozyme Pharmaceuticals, Inc.	Hairpin ribozymes
US5753613A (en)	1994-09-30	1998-05-19	Inex Pharmaceuticals Corporation	Compositions for the introduction of polyanionic materials into cells
US5885613A (en)	1994-09-30	1999-03-23	The University Of British Columbia	Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5820873A (en)	1994-09-30	1998-10-13	The University Of British Columbia	Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5872241A (en)	1995-01-25	1999-02-16	The Trustees Of Columbia University In The City Of New York	Multiple component RNA catalysts and uses thereof
CA2225460A1 (en) *	1995-06-23	1997-01-09	Winston Campbell Patterson	Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
US6346398B1 (en) *	1995-10-26	2002-02-12	Ribozyme Pharmaceuticals, Inc.	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
WO1997026270A2 (en)	1996-01-16	1997-07-24	Ribozyme Pharmaceuticals, Inc.	Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules
US5849902A (en)	1996-09-26	1998-12-15	Oligos Etc. Inc.	Three component chimeric antisense oligonucleotides
DE69736840T2 (de)	1996-12-24	2007-08-09	Sirna Therapeutics, Inc., Boulder	Synthese von nukleosiden und polynukleotiden
AU7976198A (en)	1997-06-19	1999-01-04	Ribozyme Pharmaceuticals, Inc.	Hammerhead ribozymes with extended cleavage rule
WO1999004819A1 (en)	1997-07-24	1999-02-04	Inex Pharmaceuticals Corporation	Liposomal compositions for the delivery of nucleic acid catalysts
JP2001518292A (ja)	1997-09-22	2001-10-16	マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ	エンドヌクレアーゼ活性を有する核酸触媒
US7148342B2 (en) *	2002-07-24	2006-12-12	The Trustees Of The University Of Pennyslvania	Compositions and methods for sirna inhibition of angiogenesis

1996
- 1996-01-11 US US08/584,040 patent/US6346398B1/en not_active Expired - Lifetime
- 1996-10-25 AU AU76662/96A patent/AU7666296A/en not_active Abandoned
- 1996-10-25 DE DE69638198T patent/DE69638198D1/de not_active Expired - Lifetime
- 1996-10-25 EP EP96939515A patent/EP0859837A2/en not_active Ceased
- 1996-10-25 JP JP9515329A patent/JP2000504925A/ja not_active Ceased
- 1996-10-25 WO PCT/US1996/017480 patent/WO1997015662A2/en not_active Ceased
- 1996-10-25 CA CA002235368A patent/CA2235368A1/en not_active Abandoned
1999
- 1999-08-10 US US09/371,772 patent/US6566127B1/en not_active Expired - Fee Related
2000
- 2000-10-10 US US09/685,664 patent/US6818447B1/en not_active Expired - Lifetime
2004
- 2004-09-27 US US10/951,303 patent/US20050227937A1/en not_active Abandoned
2008
- 2008-07-09 US US12/170,393 patent/US20090170197A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20050227937A1 (en)	2005-10-13
JP2000504925A (ja)	2000-04-25
US6566127B1 (en)	2003-05-20
US20090170197A1 (en)	2009-07-02
AU7666296A (en)	1997-05-15
DE69638198D1 (de)	2010-07-22
US6346398B1 (en)	2002-02-12
WO1997015662A2 (en)	1997-05-01
US6818447B1 (en)	2004-11-16
EP0859837A2 (en)	1998-08-26
WO1997015662A3 (en)	1997-07-10
MX9803354A (es)	1998-09-30

Legal Events

Date	Code	Title	Description
1999-07-13	EEER	Examination request
2005-10-25	FZDE	Discontinued

Publication	Publication Date	Title
CA2235368A1 (en)	1997-05-01	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US7034009B2 (en)	2006-04-25	Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US6057156A (en)	2000-05-02	Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
US5646042A (en)	1997-07-08	C-myb targeted ribozymes
US20030216335A1 (en)	2003-11-20	Method and reagent for the modulation of female reproductive diseases and conditions
CA2199727A1 (en)	1996-03-28	Ribozyme treatment of diseases or conditions related to levels of plasma lipoprotein (a) ¬lp(a)\| by inhibiting apolipoprotein (a) ¬apo(a)\|
JP2009000106A (ja)	2009-01-08	女性生殖疾病及び状態の核酸に基づく調節
US6183959B1 (en)	2001-02-06	Method for target site selection and discovery
US6103890A (en)	2000-08-15	Enzymatic nucleic acids that cleave C-fos
WO1998032846A9 (en)	1998-12-17	Enzymatic nucleic acid treatment of diseases or conditions related to levels of c-fos
US20040102389A1 (en)	2004-05-27	Nucleic acid-mediated treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
AU757789B2 (en)	2003-03-06	Method and reagents for the treatment of diseases or conditions related to molecules involved in angiogenic responses
EP1408111B1 (en)	2010-06-09	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
AU769175B2 (en)	2004-01-15	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
WO2001062911A2 (en)	2001-08-30	Antisense and catalytically acting nucleic acid molecules targeted to grb2- related with insert domain (grid) proteins and their uses
MXPA98003354A (en)	1998-11-16	Reagent for the treatment of diseases or disorders related to levels of vascular endothelial growth receptor and its
MXPA00009431A (es)	2002-05-09	Metodos y reactivos para el tratamiento de enfermedades o condiciones relacionadas con moleculas involucradas en respuestas angiogenicas
AU3918899A (en)	1999-09-16	Methods and compositions for treatment of restenosis and cancer using ribozymes